ZIGNEGO, ANNA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.974
EU - Europa 17.517
AS - Asia 9.952
SA - Sud America 1.382
OC - Oceania 318
AF - Africa 309
Continente sconosciuto - Info sul continente non disponibili 8
Totale 58.460
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.741
RU - Federazione Russa 7.122
PL - Polonia 3.077
SG - Singapore 2.909
HK - Hong Kong 2.309
IE - Irlanda 1.846
CN - Cina 1.791
SE - Svezia 1.448
IT - Italia 1.338
KR - Corea 1.184
BR - Brasile 1.155
UA - Ucraina 723
DE - Germania 651
FI - Finlandia 577
VN - Vietnam 487
IN - India 411
TR - Turchia 341
AU - Australia 314
GB - Regno Unito 311
CI - Costa d'Avorio 167
CA - Canada 133
FR - Francia 132
ID - Indonesia 114
AR - Argentina 89
JP - Giappone 76
JO - Giordania 65
BD - Bangladesh 58
ES - Italia 58
MX - Messico 58
NL - Olanda 55
BE - Belgio 49
IQ - Iraq 44
EC - Ecuador 40
ZA - Sudafrica 36
CH - Svizzera 31
CO - Colombia 29
MA - Marocco 27
PK - Pakistan 23
SC - Seychelles 18
VE - Venezuela 18
CZ - Repubblica Ceca 17
PY - Paraguay 16
SA - Arabia Saudita 16
UZ - Uzbekistan 16
EG - Egitto 14
MY - Malesia 13
AE - Emirati Arabi Uniti 12
KE - Kenya 11
LT - Lituania 11
PE - Perù 11
RO - Romania 11
UY - Uruguay 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
BG - Bulgaria 9
DZ - Algeria 9
IL - Israele 9
AT - Austria 8
CL - Cile 8
EU - Europa 8
JM - Giamaica 7
KG - Kirghizistan 7
AM - Armenia 6
DK - Danimarca 6
TN - Tunisia 6
ET - Etiopia 5
HN - Honduras 5
PT - Portogallo 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
BY - Bielorussia 4
CR - Costa Rica 4
KZ - Kazakistan 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
SY - Repubblica araba siriana 4
AL - Albania 3
BH - Bahrain 3
BZ - Belize 3
GR - Grecia 3
HU - Ungheria 3
IR - Iran 3
KH - Cambogia 3
LB - Libano 3
LV - Lettonia 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
TH - Thailandia 3
AO - Angola 2
BF - Burkina Faso 2
BJ - Benin 2
CY - Cipro 2
GD - Grenada 2
GE - Georgia 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 58.432
Salva come PNG Salva come JPEG
Città #
Santa Clara 6.339
Warsaw 3.065
Fairfield 2.633
Ashburn 1.952
Hong Kong 1.853
Dublin 1.844
Chandler 1.762
Singapore 1.747
Seoul 1.178
Woodbridge 1.162
Cambridge 1.092
Seattle 1.056
Jacksonville 1.013
Wilmington 956
Houston 924
Beijing 650
Princeton 565
Buffalo 516
Altamura 480
Ann Arbor 463
Lawrence 437
Boston 377
Los Angeles 368
Hefei 333
Mumbai 317
Boardman 313
Melbourne 305
Medford 269
Izmir 259
Florence 254
Moscow 216
The Dalles 195
Abidjan 167
Dallas 153
San Diego 145
Norwalk 144
Ho Chi Minh City 134
Munich 134
Shanghai 121
Dong Ket 118
Falls Church 113
São Paulo 86
Jakarta 84
Hanoi 82
Redondo Beach 81
Bremen 80
New York 74
Toronto 70
Hillsboro 67
Tokyo 67
San Jose 66
Clifton 65
Milan 58
Andover 55
Turku 54
Dearborn 53
Paris 51
Brussels 46
Kent 44
Frankfurt am Main 42
London 41
Chicago 35
Rome 34
Washington 34
Helsinki 33
Frankfurt Am Main 32
Salerno 31
Redmond 30
West Jordan 30
Bern 29
Yubileyny 29
Auburn Hills 28
Rio de Janeiro 28
Brooklyn 27
Verona 25
Barcelona 23
Phoenix 23
Stockholm 23
Atlanta 22
Belo Horizonte 21
Johannesburg 21
Laurel 21
Saint Petersburg 21
Brasília 20
Montreal 20
Porto Alegre 20
Curitiba 19
Chandigarh 18
Denver 18
Istanbul 17
Old Bridge 17
Tianjin 17
Da Nang 16
Guangzhou 16
Secaucus 16
Tashkent 16
Brno 15
Dhaka 15
Guayaquil 15
Mexico City 14
Totale 38.277
Salva come PNG Salva come JPEG
Nome #
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients 1.181
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 323
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 311
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 299
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 294
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 279
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 277
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition 252
HCV and lymphoproliferation 248
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. 244
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 244
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 243
Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome 239
Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis 237
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 234
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 234
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 227
HCV Patients Psychopathology and Tryptophan Metabolism: Analysis of the Effects of Pegylated Interferon plus Ribavirin Treatment 224
Mixed cryoglobulinemia, lymphomas and HCV 217
Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases 213
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 209
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 209
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 206
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 202
B-cells and mixed cryoglobulinemia 201
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 201
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 200
Strategie terapeutiche nella crioglobulinemia mista: recenti acquisizioni 199
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 199
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 198
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 197
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 197
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 195
AISF position paper on HCV in immunocompromised patients 194
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 194
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 193
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 192
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 192
Clinical significance of polymorphisms in immune response genes in hepatitis C-related hepatocellular carcinoma 190
Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning 189
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 189
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 188
Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma 185
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 183
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 183
International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement 182
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 182
Host genetic determinants in HCV-related mixed cryoglobulinemia 180
Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC 178
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study 178
Hepatocellular carcinoma in mixed cryoglobulinemia patients 175
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 175
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 175
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection 175
Current and future challenges in HCV: insights from an Italian experts panel 174
IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection 171
Host genetic determinants in HCV-related mixed cryoglobulinemia 171
From current status to optimization of HCV treatment: Recommendations from an expert panel 171
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 168
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 167
Analysis of HCV persistence in patients with sustained virological response 166
Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study 166
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 165
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 164
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 164
MR-diffusion imaging in assessing chronic liver diseases: does a clinical role exist? 164
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 163
Infection of peripheral mononuclear blood cells by hepatitis C virus 163
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 161
CD81 Modulation by Immobilized Monoclonal Antibodies is Able to Promote B-cell proliferation and C-MYC expression 161
Real life experiences in HCV management in 2018 161
Treatment of HCV-related mixed cryoglobulinemia 161
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) 160
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 160
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 159
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 159
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 159
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 158
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 157
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany 156
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 156
Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials 155
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 155
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non- Hodgkin's lymphoma, and cancer 154
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 153
Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis 153
Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment 153
HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation 152
CD81 MODULATION BY IMMOBILIZED MONOCLONAL ANTIBODIES IS ABLE TO PROMOTE B-CELL PROLIFERATION AND C-MYC EXPRESSION 151
Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia 150
Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients 149
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 149
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 149
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 149
Involvement of PI3K in HCV-related lymphoproliferative disorders 148
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 148
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 148
T(14;18) translocation in chronic hepatitis C virus infection 147
Can type C hepatitis infection be complicated by malignant lymphoma? 147
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection 147
Totale 19.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.285
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 162.285
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.071 0 0 0 0 0 640 194 436 426 778 253 344
2021/20223.285 49 397 150 154 112 129 109 212 120 98 543 1.212
2022/20237.696 875 1.073 303 535 729 1.661 964 385 770 49 239 113
2023/20242.265 142 390 574 119 143 269 35 368 36 70 61 58
2024/202518.782 711 2.158 1.388 2.815 5.866 1.983 197 1.035 1.191 406 560 472
2025/20269.603 2.175 2.832 1.356 1.199 1.975 66 0 0 0 0 0 0
Totale 58.687